TrialBMC neurology2022

A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC").

Jan Smeitink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.